Compare NetApp Inc. (NTAP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs TG Therapeutics Inc — how do they compare? NetApp Inc. trades at $167.96 (market cap $31.57B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: NetApp Inc. is far larger — about 3.8× TG Therapeutics Inc's market cap, and NetApp Inc. pays a 1.29% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NTAP | TGTX | |
|---|---|---|
Market Cap | $31.57B | $8.26B |
Sector | Technology | Health |
52-Week High | $181.08 | $59.06 |
52-Week Low | $94.11 | $26.39 |
Enterprise Value | $30.72B | $8.50B |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTAP trades at $165.70, up 1.11% today, near its consensus price target of $167.45. The stock shows strong fundamentals with a net income margin of 18.43% and consistent earnings beats in recent quarters. Recent acquisition of DataPelago aims to bolster AI infrastructure capabilities, while technical indicators signal a neutral near-term trend with support at $160 and resistance at $166.
Outlook remains positive driven by AI and cloud demand, though high valuation ratios like P/E of 25.38 and debt-to-asset ratio of 29.89 pose risks. Analysts are mixed with 36.6% buy ratings, suggesting cautious optimism for growth trajectory amid competitive pressures.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
